{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:58:26Z","timestamp":1773154706350,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Despite growing evidence for bilateral pelvic radiotherapy (whole pelvis RT, WPRT) there is almost no data on unilateral RT (hemi pelvis RT, HPRT) in patients with nodal recurrent prostate cancer after prostatectomy. Nevertheless, in clinical practice HPRT is sometimes used with the intention to reduce side effects compared to WPRT. Prostate-specific membrane antigen positron emission tomography \/ computed tomography (PSMA-PET\/CT) is currently the best imaging modality in this clinical situation. This analysis compares PSMA-PET\/CT based WPRT and HPRT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A propensity score matching was performed in a multi-institutional retrospective dataset of 273 patients treated with pelvic RT due to nodal recurrence (214 WPRT, 59 HPRT). In total, 102 patients (51 in each group) were included in the final analysis. Biochemical recurrence-free survival (BRFS) defined as prostate specific antigen (PSA)\u2009&lt;\u2009post-RT nadir\u2009+\u20090.2ng\/ml, metastasis-free survival (MFS) and nodal recurrence-free survival (NRFS) were calculated using the Kaplan-Meier method and compared using the log rank test.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Median follow-up was 29 months. After propensity matching, both groups were mostly well balanced. However, in the WPRT group there were still significantly more patients with additional local recurrences and biochemical persistence after prostatectomy. There were no significant differences between both groups in BRFS (<jats:italic>p<\/jats:italic>\u2009=\u2009.97), MFS (<jats:italic>p<\/jats:italic>\u2009=\u2009.43) and NRFS (<jats:italic>p<\/jats:italic>\u2009=\u2009.43). After two years, BRFS, MFS and NRFS were 61%, 86% and 88% in the WPRT group and 57%, 90% and 82% in the HPRT group, respectively. Application of a boost to lymph node metastases, a higher RT dose to the lymphatic pathways (&gt;\u200950\u00a0Gy EQD2<jats:sub>\u03b1\/\u03b2=1.5\u00a0Gy<\/jats:sub>) and concomitant androgen deprivation therapy (ADT) were significantly associated with longer BRFS in uni- and multivariate analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Overall, this analysis presents the outcome of HPRT in nodal recurrent prostate cancer patients and shows that it can result in a similar oncologic outcome compared to WPRT. Nevertheless, patients in the WPRT may have been at a higher risk for progression due to some persistent imbalances between the groups. Therefore, further research should prospectively evaluate which subgroups of patients are suitable for HPRT and if HPRT leads to a clinically significant reduction in toxicity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-024-06802-x","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T10:02:16Z","timestamp":1719568936000},"page":"3770-3781","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5382-5933","authenticated-orcid":false,"given":"Christian","family":"Trapp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Aebersold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jozefina","family":"Casuscelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chukwuka","family":"Eze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Farolfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca-Ligia","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Hruby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Kirste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan A.","family":"Koerber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Kroeze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan C.","family":"Peeken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Rogowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Scharl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Shelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon K. B.","family":"Spohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iosif","family":"Strouthos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantinos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina-Sophie","family":"Schmidt-Hegemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"6802_CR1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000045749.90353.c7","author":"M Han","year":"2003","unstructured":"Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer [eng]. J Urol. 2003. https:\/\/doi.org\/10.1097\/01.ju.0000045749.90353.c7.","journal-title":"J Urol"},{"key":"6802_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000134888.22332.bb","author":"KA Roehl","year":"2004","unstructured":"Roehl KA, Han M, Ramos CG, Antenor JAV, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results [eng]. J Urol. 2004. https:\/\/doi.org\/10.1097\/01.ju.0000134888.22332.bb.","journal-title":"J Urol"},{"key":"6802_CR3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.201749","author":"J Calais","year":"2018","unstructured":"Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, et al. 68Ga-PSMA-11 PET\/CT mapping of prostate Cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA Level of Less Than 1.0 ng\/mL: impact on Salvage Radiotherapy Planning [eng]. J Nucl Med. 2018. https:\/\/doi.org\/10.2967\/jnumed.117.201749.","journal-title":"J Nucl Med"},{"key":"6802_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.01.004","author":"BA Jereczek-Fossa","year":"2017","unstructured":"Jereczek-Fossa BA, Fanetti G, Fodor C, Ciardo D, Santoro L, Francia CM, et al. Salvage stereotactic body radiotherapy for isolated Lymph Node recurrent prostate Cancer: single Institution Series of 94 consecutive patients and 124 lymph nodes [eng]. Clin Genitourin Cancer. 2017. https:\/\/doi.org\/10.1016\/j.clgc.2017.01.004.","journal-title":"Clin Genitourin Cancer"},{"key":"6802_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.04.017","author":"A Kneebone","year":"2018","unstructured":"Kneebone A, Hruby G, Ainsworth H, Byrne K, Brown C, Guo L, et al. Stereotactic body radiotherapy for oligometastatic prostate Cancer detected via prostate-specific membrane Antigen Positron Emission Tomography [eng]. Eur Urol Oncol. 2018. https:\/\/doi.org\/10.1016\/j.euo.2018.04.017.","journal-title":"Eur Urol Oncol"},{"key":"6802_CR6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4853","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, de Bruycker A, et al. Surveillance or Metastasis-Directed therapy for oligometastatic prostate Cancer recurrence: a prospective, randomized, Multicenter Phase II trial [eng]. JCO. 2018. https:\/\/doi.org\/10.1200\/JCO.2017.75.4853.","journal-title":"JCO"},{"key":"6802_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0147","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for oligometastatic prostate Cancer: the ORIOLE phase 2 Randomized Clinical Trial [eng]. JAMA Oncol. 2020. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0147.","journal-title":"JAMA Oncol"},{"key":"6802_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.05.004","author":"S Harrow","year":"2022","unstructured":"Harrow S, Palma DA, Olson R, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): extended long-term outcomes [eng]. Int J Radiat Oncol Biol Phys. 2022. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.004.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6802_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.06.004","author":"S Siva","year":"2018","unstructured":"Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J, et al. Stereotactic abative body Radiotherapy (SABR) for oligometastatic prostate Cancer: a prospective clinical trial [eng]. Eur Urol. 2018. https:\/\/doi.org\/10.1016\/j.eururo.2018.06.004.","journal-title":"Eur Urol"},{"key":"6802_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00644","author":"MP Deek","year":"2022","unstructured":"Deek MP, van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, et al. Long-term outcomes and genetic predictors of response to Metastasis-Directed Therapy Versus Observation in oligometastatic prostate Cancer: analysis of STOMP and ORIOLE trials [eng]. J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.22.00644.","journal-title":"J Clin Oncol"},{"key":"6802_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000419","author":"S Tran","year":"2018","unstructured":"Tran S, Jorcano S, Falco T, Lamanna G, Miralbell R, Zilli T. Oligorecurrent nodal prostate Cancer: long-term results of an Elective nodal Irradiation Approach [eng]. Am J Clin Oncol. 2018. https:\/\/doi.org\/10.1097\/COC.0000000000000419.","journal-title":"Am J Clin Oncol"},{"key":"6802_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13510","author":"A Fodor","year":"2017","unstructured":"Fodor A, Berardi G, Fiorino C, Picchio M, Busnardo E, Kirienko M, et al. Toxicity and efficacy of salvage carbon 11-choline positron emission tomography\/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer [eng]. BJU Int. 2017. https:\/\/doi.org\/10.1111\/bju.13510.","journal-title":"BJU Int"},{"key":"6802_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05557-z","author":"P Rogowski","year":"2022","unstructured":"Rogowski P, Trapp C, von Bestenbostel R, Eze C, Ganswindt U, Li M, et al. Outcome after PSMA-PET\/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy [eng]. Eur J Nucl Med Mol Imaging. 2022. https:\/\/doi.org\/10.1007\/s00259-021-05557-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6802_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153766","author":"J Tamihardja","year":"2022","unstructured":"Tamihardja J, Zehner L, Hartrampf P, Lisowski D, Kneitz S, Cirsi S, et al. Salvage nodal Radiotherapy as Metastasis-Directed therapy for oligorecurrent prostate Cancer detected by Positron Emission Tomography shows favorable outcome in Long-Term Follow-Up [eng]. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14153766.","journal-title":"Cancers (Basel)"},{"key":"6802_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.06.010","author":"S Supiot","year":"2021","unstructured":"Supiot S, Vaugier L, Pasquier D, Buthaud X, Magn\u00e9 N, Peiffert D, et al. OLIGOPELVIS GETUG P07, a Multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in Oligorecurrent pelvic node relapses in prostate Cancer [eng]. Eur Urol. 2021. https:\/\/doi.org\/10.1016\/j.eururo.2021.06.010.","journal-title":"Eur Urol"},{"key":"6802_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.07.009","author":"E de Bleser","year":"2019","unstructured":"de Bleser E, Jereczek-Fossa BA, Pasquier D, Zilli T, van As N, Siva S, et al. Metastasis-directed therapy in treating nodal oligorecurrent prostate Cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy [eng]. Eur Urol. 2019. https:\/\/doi.org\/10.1016\/j.eururo.2019.07.009.","journal-title":"Eur Urol"},{"key":"6802_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06911-4","author":"A de Bruycker","year":"2020","unstructured":"de Bruycker A, Spiessens A, Dirix P, Koutsouvelis N, Semac I, Liefhooghe N, et al. PEACE V - salvage treatment of OligoRecurrent nodal prostate cancer metastases (STORM): a study protocol for a randomized controlled phase II trial [eng]. BMC Cancer. 2020. https:\/\/doi.org\/10.1186\/s12885-020-06911-4.","journal-title":"BMC Cancer"},{"key":"6802_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.08.066","author":"A Soldatov","year":"2019","unstructured":"Soldatov A, von Klot CAJ, Walacides D, Derlin T, Bengel FM, Ross TL, et al. Patterns of Progression after 68Ga-PSMA-Ligand PET\/CT-Guided Radiation Therapy for recurrent prostate Cancer [eng]. Int J Radiat Oncol Biol Phys. 2019. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.08.066.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6802_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06445-4","author":"A Fodor","year":"2024","unstructured":"Fodor A, Brombin C, Deantoni CL, Giannini L, Ferrario F, Villa SL, et al. Extended nodal radiotherapy for prostate cancer relapse guided with [11\u00a0C]-choline PET\/CT: ten-year results in patients enrolled in a prospective trial. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-023-06445-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6802_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14748","author":"C Zamboglou","year":"2023","unstructured":"Zamboglou C, Peeken JC, Janbain A, Katsahian S, Strouthos I, Ferentinos K, et al. Development and validation of a multi-institutional Nomogram of outcomes for PSMA-PET-Based salvage radiotherapy for recurrent prostate Cancer [eng]. JAMA Netw Open. 2023. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.14748.","journal-title":"JAMA Netw Open"},{"key":"6802_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-021-01871-5","author":"S Cozzi","year":"2022","unstructured":"Cozzi S, Botti A, Timon G, Blandino G, Najafi M, Manicone M, et al. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer: an investigation of 117 pelvic lymph nodes. Strahlenther Onkol. 2022. https:\/\/doi.org\/10.1007\/s00066-021-01871-5.","journal-title":"Strahlenther Onkol"},{"key":"6802_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59081442","author":"F Cuccia","year":"2023","unstructured":"Cuccia F, Tamburo M, Piras A, Mortellaro G, Iudica A, Daidone A, et al. Stereotactic body radiotherapy for lymph-nodal oligometastatic prostate Cancer: a Multicenter Retrospective experience [eng]. Med (Kaunas). 2023. https:\/\/doi.org\/10.3390\/medicina59081442.","journal-title":"Med (Kaunas)"},{"key":"6802_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-019-01523-9","author":"L Nicosia","year":"2020","unstructured":"Nicosia L, Franzese C, Mazzola R, Franceschini D, Rigo M, D\u2019agostino G, et al. Rezidivmuster Nach Stereotaktischer Radiotherapie beim oligometastasierten Prostatakarzinom: eine multiinstitutionelle Analyse. [Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis] [eng]. Strahlenther Onkol. 2020. https:\/\/doi.org\/10.1007\/s00066-019-01523-9.","journal-title":"Strahlenther Onkol"},{"key":"6802_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.08.034","author":"WA Hall","year":"2021","unstructured":"Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, et al. NRG Oncology Updated International Consensus Atlas on pelvic lymph node volumes for Intact and postoperative prostate Cancer [eng]. Int J Radiat Oncol Biol Phys. 2021. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.08.034.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6802_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01790-6","author":"A Pollack","year":"2022","unstructured":"Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022. https:\/\/doi.org\/10.1016\/S0140-6736(21)01790-6.","journal-title":"Lancet"},{"key":"6802_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.09.007","author":"P Ost","year":"2023","unstructured":"Ost P, Siva S, Brabrand S, Dirix P, Liefhooghe N, Otte F-X, et al. PEACE V-Salvage treatment of OligoRecurrent nodal prostate cancer metastases (STORM): Acute Toxicity of a Randomized phase 2 trial [eng]. Eur Urol Oncol. 2023. https:\/\/doi.org\/10.1016\/j.euo.2023.09.007.","journal-title":"Eur Urol Oncol"},{"key":"6802_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.06.2455","author":"P Pommier","year":"2016","unstructured":"Pommier P, Chabaud S, Lagrange J-L, Richaud P, Le Prise E, Wagner J-P, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study [eng]. Int J Radiat Oncol Biol Phys. 2016. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.06.2455.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6802_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30528-X","author":"M Roach","year":"2018","unstructured":"Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, et al. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial [eng]. Lancet Oncol. 2018. https:\/\/doi.org\/10.1016\/S1470-2045(18)30528-X.","journal-title":"Lancet Oncol"},{"key":"6802_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03282","author":"V Murthy","year":"2021","unstructured":"Murthy V, Maitre P, Kannan S, Panigrahi G, Krishnatry R, Bakshi G, et al. Prostate-only Versus Whole-Pelvic Radiation Therapy in High-Risk and very high-risk prostate Cancer (POP-RT): outcomes from phase III randomized controlled trial [eng]. J Clin Oncol. 2021. https:\/\/doi.org\/10.1200\/JCO.20.03282.","journal-title":"J Clin Oncol"},{"key":"6802_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00728-5","author":"F Preisser","year":"2023","unstructured":"Preisser F, Incesu R-B, Rajwa P, Chlosta M, Nohe F, Ahmed M, et al. Impact of persistent PSA after salvage radical prostatectomy: a multicenter study [eng]. Prostate Cancer Prostatic Dis. 2023. https:\/\/doi.org\/10.1038\/s41391-023-00728-5.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"6802_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.09.039","author":"T Wiegel","year":"2015","unstructured":"Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, St\u00f6ckle M, et al. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96\u2009\u2013\u200902 trial [eng]. Int J Radiat Oncol Biol Phys. 2015. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.09.039.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6802_CR32","doi-asserted-by":"publisher","unstructured":"Francini E, Gray KP, Xie W, Shaw GK, Valen\u00e7a L, Bernard B et al. Time of Metastatic Disease Presentation and Volume of Disease are Prognostic for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) [eng]. Prostate. 2018; https:\/\/doi.org\/10.1002\/pros.23645.","DOI":"10.1002\/pros.23645"},{"key":"6802_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-675","author":"F Cuppone","year":"2010","unstructured":"Cuppone F, Bria E, Giannarelli D, Vaccaro V, Milella M, Nistic\u00f2 C, et al. Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. BMC Cancer. 2010. https:\/\/doi.org\/10.1186\/1471-2407-10-675.","journal-title":"BMC Cancer"},{"key":"6802_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.064","author":"CC Parker","year":"2022","unstructured":"Parker CC, Clarke N, Cook A, Catton C, Cross WR, Kynaston H, et al. LBA9 duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: first results of the RADICALS-HD trial (ISRCTN40814031). Ann Oncol. 2022. https:\/\/doi.org\/10.1016\/j.annonc.2022.08.064.","journal-title":"Ann Oncol"},{"key":"6802_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3771","author":"TA Hope","year":"2021","unstructured":"Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial [eng]. JAMA Oncol. 2021. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3771.","journal-title":"JAMA Oncol"},{"key":"6802_CR36","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181fc679e","author":"Y Tokuda","year":"2010","unstructured":"Tokuda Y, Carlino LJ, Gopalan A, Tickoo SK, Kaag MG, Guillonneau B, et al. Prostate cancer topography and patterns of lymph node metastasis [eng]. Am J Surg Pathol. 2010. https:\/\/doi.org\/10.1097\/PAS.0b013e3181fc679e.","journal-title":"Am J Surg Pathol"},{"key":"6802_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.07.043","author":"DE Spratt","year":"2017","unstructured":"Spratt DE, Vargas HA, Zumsteg ZS, Golia Pernicka JS, Osborne JR, Pei X, et al. Patterns of Lymph Node Failure after dose-escalated Radiotherapy: implications for extended pelvic lymph Node Coverage [eng]. Eur Urol. 2017. https:\/\/doi.org\/10.1016\/j.eururo.2016.07.043.","journal-title":"Eur Urol"},{"key":"6802_CR38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303974","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, de Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved outcomes with Enzalutamide in biochemically recurrent prostate Cancer [eng]. N Engl J Med. 2023. https:\/\/doi.org\/10.1056\/NEJMoa2303974.","journal-title":"N Engl J Med"},{"key":"6802_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02437-5","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol [eng]. Lancet. 2022. https:\/\/doi.org\/10.1016\/S0140-6736(21)02437-5.","journal-title":"Lancet"},{"key":"6802_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.01.005","author":"RL Bitting","year":"2021","unstructured":"Bitting RL, Healy P, George DJ, Anand M, Kim S, Mayer T, et al. Phase II trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in men with high-risk prostate-specific Antigen recurrent prostate Cancer: the STREAM trial [eng]. Eur Urol Oncol. 2021. https:\/\/doi.org\/10.1016\/j.euo.2020.01.005.","journal-title":"Eur Urol Oncol"},{"key":"6802_CR41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01662","author":"PT Tran","year":"2023","unstructured":"Tran PT, Lowe K, Tsai H-L, Song DY, Hung AY, Hearn JWD, et al. Phase II randomized study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk prostate-specific Antigen recurrent prostate Cancer after Radical Prostatectomy: the SALV-ENZA trial [eng]. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/JCO.22.01662.","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06802-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T05:29:22Z","timestamp":1727760562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06802-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["6802"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06802-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]},"assertion":[{"value":"13 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This multi-institutional retrospective analysis followed the \u201cStrengthening the Reporting of Observational Studies in Epidemiology\u201d (STROBE) reporting guideline. It was approved by local ethics committees of all participating centers (University of Freiburg, Freiburg, Germany; University of Munich, Munich, Germany; Technical University of Munich, Munich, Germany; University of Bologna, Bologna, Italy; University of Ulm, Ulm, Germany; Ethics Committee Zuerich, Zuerich, Switzerland; University of New South Wales, Sydney, Australia; University of Heidelberg, Heidelberg, Germany; Cyprus National Bioethics Committee, Nicosia, Cyprus; Cantonal Ethics Commission Bern, Bern, Switzerland).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was waived due to the retrospective character of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Stefano Fanti is member of the editorial board of this journal. All other authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}